Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS

Completed · Not applicable

Conditions studied: HIV Infections

In brief

This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55, who are currently taking ART and reporting less than 100% adherence. The aims of the study are to see whether the device can achieve \>95% ART adherence among all participants averaged over 90 days and to perform usability testing using the System Usability Scale and Net Promoter scores.

Key facts

Study ID

NCT05454514

Run by

Charles Gellman

People needed

7

Starts

2021-09-09

Expected to finish

2023-05-31

Last updated by the study team

2025-03-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-65 years of age
• Prescription for at least one existing ART
• Has expressed difficulty with medication adherence (question screen)
• Access to a personal smart phone and a Wi-Fi connection
• Ability to read and write English

You may not qualify if…

• Illicit drug use within the past 6 months (excl. marijuana)
• Diagnosis of dementia
• Clinical study participation within the previous 3 months
• Changes to ART regimen within the previous 2 months
• Anticipated change to ART therapy within the study period

Where it is running

• HiDO Technologies Inc. — El Dorado Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.